News & Updates

Addressing the obesity challenge with semaglutide

Obesity is a global epidemic that is on the rise in Singapore. One in five adults will be living with obesity in 2025, with disastrous consequences. Early intervention with semaglutide could help.

Phenotype-guided treatment for obesity: Does naltrexone/bupropion fit?

Obesity is a chronic, relapsing, multifactorial disease that results in impaired quality of life and reduced life expectancy. Lifestyle modifications involving dietary interventions, physical activity, and behavioural changes remain the cornerstone of obesity management. However, lifestyle modifications are often insufficient, making other treatment modalities, including pharmacotherapy, an important option.

Product Highlight - LYPSTAPLUS

Rosuvastatin + Ezetimibe 10/10 mg and 20/10 mg film-coated tablet

What’s new, what’s hot in diabetes management: Snippets from ATTD-ASIA

ATTD-ASIA 2024, held recently in Singapore, was a huge success, with nearly 800 delegates from 49 countries gracing the event. ATTD-Asia 2024 chair, Professor Moshe Phillip, said the event brought together top diabetes experts to ensure patients can access the latest technologies and treatments for diabetes. MIMS Doctor reports highlights and snippets from the conference.

Podcasts@ATTD-ASIA: Experts share how CGM transforms diabetes care

Podcasts@ATTD-ASIA: Experts share how CGM transforms diabetes care

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

The post-pandemic burden of COVID-19 remains significant in adults. Four studies from IDWeek 2024 highlight the benefits of nirmatrelvir-ritonavir (NMV/r) for high-risk adults with SARS-CoV-2 immunity and link chronic conditions to COVID-19 hospitalization. Identifying high-risk patients and using NMV/r in outpatient settings can reduce severe outcomes.

Clinical considerations for patients at high risk for progression to severe COVID-19

COVID-19 has not gone away. New contagious variants continue to be a leading cause of death, with underlying conditions still influencing the risk of COVID-19 hospitalizations, said Dr Ali Hassoun, Clinical Professor of Medicine and infectious disease specialist at Crestwood Medical Center, Huntsville, Alabama, US, who spoke at a Pfizer-sponsored session during IDWeek 2024.

New consensus guideline sets framework for obesity care in South and Southeast Asia

The increasing prevalence of obesity globally, including in South and Southeast Asia (S-SEA), has become a pressing public health concern, posing significant challenges to local economies, healthcare infrastructures, and individual well-being. [World Obesity Atlas 2022; https://www.worldobesityday.org/assets/downloads/World_Obesity_Atlas_2022_WEB.pdf]

Debunking the myths about DPP-4 inhibitors

Navigating the evolving landscape of diabetes management requires precise knowledge. In this exploration into the world of DPP-4 inhibitors (DPP4is), we aim to debunk prevalent myths and provide nuanced insights.

Robust evidence for fenofibrate in patients with metabolic syndrome on statins